The Taizhou Medical High Tech Zone – also known as China Medical City, located in Taizhou city, in East China's Jiangsu province – is moving to consolidate its health sector.
On Feb 16, Sino Biological (Taizhou) Co Ltd became operational, based on an investment of 150 million yuan ($21.89 million). It will provide high-quality biological reagent products and technical services both in China and overseas.
Meanwhile, Jiangsu Biointron Co Ltd has been constructing a factory since December for the R&D and production of antibodies, protein drugs, and diagnostic reagents raw materials.
The construction project, costing 500 million yuan, is expected to meet the acceptance criteria in September.
In recent years, Zhongke Health Industry Group Jiangsu Pharmaceutical Co Ltd has been focusing on R&D and relying on sci-tech innovation to support its industrial upgrading.
A look of Zhongke Health Industry Group Jiangsu Pharmaceutical Co Ltd. [Photo/WeChat account: weigg6666]
It has invested 10 million yuan to recruit talented personnel and purchase cutting-edge R&D equipment. More than 10 kinds of traditional Chinese medicine and healthy food products will be put into full production this year.
Guided by Taizhou's move to develop its healthcare sector, the zone will continue to attract new projects, improve the industrial environment, and provide professional and efficient services.